¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
Checkout the top 10 takeaways by KDIGO on the management of people with CKD. VA by Dr Vamsidhar Veeranki
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial
NSMC Intern Elba Medina creates a crisp VA for the PRAECIS trial.
Also, we have some bonus VAs this time created for NephMadness by our VA editor Divya Bajpai!
Check out the dreamy Visual Abstract by Cristina Popa
Any sleep potion for insomnia in patients on hemodialysis?
Trainee Love and Breakup Letters to NephSIM: A Free, Mobile-Optimized, Nephrology Teaching Tool (Fattah, CJASN 2023)
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)